Park Medi World Limited will host its management team for an exclusive investor session on August 22, 2026. The virtual meeting, organized by Divitiae Investments, is scheduled to commence at 11:00 am. This disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Meeting Details

The company confirmed the logistics for the upcoming engagement with market participants. The session will be conducted as a group meeting in a virtual format.

Disclosure Statement

Park Medi World emphasized that the representatives attending the conference do not intend to discuss any unpublished price-sensitive information. The schedule remains subject to change due to any exigencies on the part of the investors or the company. The full disclosure is available on the company's website.

Park Medi World Limited delivered robust financial results for the quarter ended June 30, 2026, reporting a 35% year-on-year surge in net profit to ₹89 crore, driven by strong patient volume growth and improved operational efficiency. Revenue from operations rose 19% to ₹476 crore, while EBITDA expanded 20% to ₹126 crore. The hospital group also unveiled an aggressive expansion roadmap, targeting a bed capacity of 5,740 by March 2028, largely funded through internal accruals and IPO proceeds without fresh debt.

The filing was submitted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, with Abhishek Kapoor, Company Secretary & Compliance Officer, certifying the disclosure to BSE Limited and the National Stock Exchange of India Limited. The earnings conference call, held on August 04, 2026, featured Managing Director Dr. Ankit Gupta, Whole-Time Director & CEO Dr. Sanjay Sharma, Group CFO Mr. Rajesh Sharma, and Chief Strategy Officer Mr. Sudesh Sharma.

Financial Performance

*Figures for Q1FY26 derived from disclosed growth percentages.

Group CFO Rajesh Sharma attributed the margin expansion to reduced interest outgo following substantial term debt repayment. As of June 30, 2026, term debt excluding lease liability stood at ₹25.6 crore, down from ₹28.2 crore in March 2026. The company maintained a fixed deposit of ₹300 crore and net worth of ₹2,100 crore.

Operational Metrics and Case Mix

Operational volumes showed consistent growth, with In-Patient Department (IPD) volumes rising 16% to 26,304 patients and Out-Patient Department (OPD) volumes increasing 17% to 2,23,446 patients. Average Revenue Per Occupied Bed (ARPOB) grew 12% to ₹30,444, while Average Length of Stay (ALOS) improved by 8% to 5.9 days.

The case mix shifted towards high-end tertiary and quaternary care, contributing approximately 62% of total revenue, an increase of 440 basis points year-on-year. Key specialties included neurology (14.5%), cardiology (12%), urology (11%), oncology (9-10%), joint replacement (9.5%), and gastroenterology (7%). Network occupancy moderated to 56% from 68% in Q1FY26, reflecting the immediate inclusion of 960 new beds in Bhatinda, Agra, and Panchkula in the denominator during their ramp-up phase.

Expansion Roadmap

Park Medi World commissioned The Medicity Hospital in Rudrapur, Uttarakhand, on August 2, 2026, marking its entry into its sixth state. The 330-bed NABH-accredited facility was acquired for ₹177 crore. Additionally, the company announced a definitive agreement to acquire Mehar Hospital in Zirakpur, Punjab, a 150-bed facility valued at ₹107 crore. A 100-bed extension at Palam Vihar, Gurgaon, named 'Park Platinum', will bring consolidated Gurgaon capacity to 750 beds.

Total bed capacity stood at 3,960 as of June 30, 2026, up 32% year-on-year. The company expects to add 1,490 beds in calendar year 2026, reaching 4,740 beds by end-FY27. By March 2028, capacity is projected to reach 5,740 beds. Blended CAPEX per bed is expected to remain at ₹36 lakh over FY27 and FY28, supported by ₹767 crore in planned capital expenditure for 2,130 new beds.

What the Numbers Show

The divergence between revenue growth (19%) and PAT growth (35%) highlights the leverage effect of debt reduction on bottom-line profitability. With term debt significantly lowered, interest savings are flowing directly to net profit, enhancing return on capital employed. Furthermore, the shift in payer mix towards a targeted 70:30 split (government schemes to private/self-pay) over the next 12-18 months aims to stabilize ARPOB growth within a 10-12% annual band, mitigating reliance on lower-margin government reimbursements while maintaining affordability.

Management guided full-year FY27 revenue at ₹2,080 crore, EBITDA at ₹530 crore, and PAT at ₹360 crore, implying growth rates of 24%, 25%, and 32% respectively over FY26. The CGHS rate revision, implemented in October 2025, is expected to provide a 7-7.5% benefit, though management noted that additional revenues will be reinvested into CAPEX and equipment upgrades rather than directly boosting margins.